{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:28:37Z","timestamp":1792682917505,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T00:00:00Z","timestamp":1477008000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00277-016-2847-z","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T23:10:53Z","timestamp":1477005053000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The possible role of burden of therapy on the risk of myeloma extramedullary spread"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-3083","authenticated-orcid":false,"given":"Silvia","family":"Mangiacavalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pompa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Klersy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cocito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Varettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. S.","family":"Cartia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Corso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,21]]},"reference":[{"key":"2847_CR1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021\u20131030","journal-title":"N Engl J Med"},{"key":"2847_CR2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370:1209\u20131218","journal-title":"Lancet"},{"key":"2847_CR3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906\u2013917","journal-title":"N Engl J Med"},{"key":"2847_CR4","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621\u20134629","journal-title":"J Clin Oncol"},{"key":"2847_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29\u201337","journal-title":"Lancet Oncol"},{"key":"2847_CR6","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"S Kumar","year":"2008","unstructured":"Kumar S, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520","journal-title":"Blood"},{"key":"2847_CR7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","volume":"118","author":"J Martinez-Lopez","year":"2011","unstructured":"Martinez-Lopez J, Blad\u00e8 J, Mateos MV, Grande C, Alegre A, Garcia-Larana J et al (2011) Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118:529\u2013534","journal-title":"Blood"},{"key":"2847_CR8","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","volume":"29","author":"J Blad\u00e9","year":"2011","unstructured":"Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L, Cibeira MT, Jim\u00e9nez R, Powles R et al (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29:3805\u20133812","journal-title":"J Clin Oncol"},{"key":"2847_CR9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21:325\u2013330","journal-title":"Ann Oncol"},{"key":"2847_CR10","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","volume":"54","author":"M Weinstock","year":"2013","unstructured":"Weinstock M, Ghobrial I (2013) Extramedullary multiple myeloma. Leuk Lymphoma 54:1135\u20131141","journal-title":"Leuk Lymphoma"},{"key":"2847_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/bmt.2012.26","volume":"48","author":"B Wirk","year":"2013","unstructured":"Wirk B, Wingard JR, Moreb JS (2013) Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. Bone Marrow Transplant 48:10\u201318","journal-title":"Bone Marrow Transplant"},{"key":"2847_CR12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3109\/10428194.2012.753451","volume":"54","author":"P Moreau","year":"2013","unstructured":"Moreau P, Polliack A (2013) Extramedullary multiple myeloma: extra-osseous relapse is extra \u201cbad news\u201d, but why? Leuk Lymphoma 54:1349\u20131350","journal-title":"Leuk Lymphoma"},{"key":"2847_CR13","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3109\/10428194.2012.746683","volume":"54","author":"X Papanikolaou","year":"2013","unstructured":"Papanikolaou X, Repousis P, Tzenou T, Maltezas D, Kotsopoulou M, Megalakaki K et al (2013) Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma 54:1459\u20131464","journal-title":"Leuk Lymphoma"},{"key":"2847_CR14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A et al (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97:1761\u20131767","journal-title":"Haematologica"},{"key":"2847_CR15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","volume":"25","author":"KD Short","year":"2011","unstructured":"Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A et al (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25:906\u2013908","journal-title":"Leukemia"},{"key":"2847_CR16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L et al (2014) Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 99:360\u2013417","journal-title":"Haematologica"},{"issue":"Jimenez R","key":"2847_CR17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/bmt.2013.150","volume":"49","author":"C Fernandez de Larrea","year":"2014","unstructured":"Fernandez de Larrea C, Jimenez R, Rosinol L, Gine\u2019 L, Tovar N, Cibeira MT et al (2014) Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplant 49(Jimenez R):223\u2013227","journal-title":"Bone Marrow Transplant"},{"key":"2847_CR18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.13383","volume":"169","author":"M Weinstock","year":"2015","unstructured":"Weinstock M, Aljawai Y, Morgan E et al (2015) Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol 169:851\u2013858","journal-title":"Br J Haematol"},{"key":"2847_CR19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bjh.13382","volume":"169","author":"C Varga","year":"2015","unstructured":"Varga C, Wanling X, Laubach J, Ghobrial IM, O\u2019Donnel EK, Weinstock M et al (2015) Development of extramedullary myeloma in the era of novel agent: no evidence of increased risk with lenalidomide-bortezomib combination. Br J Haematol 169:843\u2013850","journal-title":"Br J Haematol"},{"key":"2847_CR20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bjh.13384","volume":"169","author":"J Blade","year":"2015","unstructured":"Blade J, Fernadez de Larrea C, Rosinol L (2015) Extramedullary disease in multiple myeloma in the era of novel agents. Br J Haematol 169:763\u2013765","journal-title":"Br J Haematol"},{"key":"2847_CR21","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00277-015-2484-y","volume":"94","author":"E Katodritou","year":"2015","unstructured":"Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P et al (2015) Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Ann Hematol 94:2033\u20132042","journal-title":"Ann Hematol"},{"issue":"8","key":"2847_CR22","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","volume":"127","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Moreau P (2016) How I treat extramedullary myeloma. Blood 127(8):971\u2013976","journal-title":"Blood"},{"key":"2847_CR23","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","volume":"121","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N et al (2013) Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 121:1819\u20131823","journal-title":"Blood"},{"key":"2847_CR24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjh.12007","volume":"159","author":"E Zamagni","year":"2012","unstructured":"Zamagni E, Cavo M (2012) The role of imaging techniques in the management of multiple myeloma. Br J Haematol 159:499\u2013513","journal-title":"Br J Haematol"},{"key":"2847_CR25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","volume":"28","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R et al (2014) International Myeloma Working Group recommendation for global myeloma care. Leukemia 28:981\u2013992","journal-title":"Leukemia"},{"key":"2847_CR26","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.ejrad.2014.09.012","volume":"63","author":"C Mesgnich","year":"2014","unstructured":"Mesgnich C, Fardanesh R, Tenembaum L, Chari A, Jagannath S, Kostakoglu L (2014) State of the art imaging in multiple myeloma: comparative review of FDG-PET\/CT imaging in various clinical settings. Eur J Rad 63:2203\u20132223","journal-title":"Eur J Rad"},{"key":"2847_CR27","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/RLU.0000000000000902","volume":"41","author":"SH Tirumani","year":"2016","unstructured":"Tirumani SH, Sakellis C, Jacene H, Shinagare AB, Munshi NC, Ramaiya NH et al (2016) Role of FDG-PET\/CT in extramedullary multiple myeloma: correlation of FDG-PET\/CT findings with clinical outcome. Clin Nucl Med 41:e7\u2013e13","journal-title":"Clin Nucl Med"},{"issue":"19","key":"2847_CR28","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","volume":"21","author":"E Zamagni","year":"2015","unstructured":"Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L et al (2015) PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res 21(19):4384\u20134390","journal-title":"Clin Cancer Res"},{"key":"2847_CR29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","volume":"27","author":"C Fern\u00e1ndez de Larrea","year":"2013","unstructured":"Fern\u00e1ndez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH et al (2013) Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27:780\u2013791","journal-title":"Leukemia"},{"key":"2847_CR30","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.leu.2404085","volume":"20","author":"JA P\u00e9rez-Sim\u00f3n","year":"2006","unstructured":"P\u00e9rez-Sim\u00f3n JA, Sureda A, Fern\u00e1ndez-Aviles F, Sampol A, Cabrera JR, Caballero D et al (2006) Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 20:542\u2013545","journal-title":"Leukemia"},{"key":"2847_CR31","first-page":"787809","volume":"2015","author":"X Qu","year":"2015","unstructured":"Qu X, Chen L, Qiu H, Lu H, Wu H, Qiu H et al (2015) Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance. Biomed Res Int 2015:787809, Epub 2015 Apr 23","journal-title":"Biomed Res Int"},{"key":"2847_CR32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481:306\u2013313","journal-title":"Nature"},{"key":"2847_CR33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12:335\u2013348","journal-title":"Nat Rev Cancer"},{"key":"2847_CR34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067\u20131076","journal-title":"Blood"},{"key":"2847_CR35","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","volume":"120","author":"JB Egan","year":"2012","unstructured":"Egan JB, Shi CX, Tembe W, Christoforides A, KJurdoglu A, Sinari S et al (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120:1060\u20131066","journal-title":"Blood"},{"key":"2847_CR36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2012.226","volume":"27","author":"F Magrangeas","year":"2013","unstructured":"Magrangeas F, Avet-Loiseau H, Gouraud W, Lode\u2019 L, Decaux O, Godmer P et al (2013) Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27:473\u2013481","journal-title":"Leukemia"},{"key":"2847_CR37","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, Van Lool P, Alexandrov LB, Martincorena I et al (2014) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997","journal-title":"Nat Commun"},{"key":"2847_CR38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.12805","volume":"165","author":"A Brioli","year":"2014","unstructured":"Brioli A, Melchor L, Cavo M, Morgan GJ (2014) The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol 165:441\u2013454","journal-title":"Br J Haematol"},{"key":"2847_CR39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5507\/bp.2015.014","volume":"159","author":"S Sevcikova","year":"2015","unstructured":"Sevcikova S, Paszekova H, Besse L, Sedlarikova L, Kubaczkova V, Almasi M et al (2015) Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159:88\u201393","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2847-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2847-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2847-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T02:53:08Z","timestamp":1718851988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2847-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["2847"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2847-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,21]]}}}